Rektal Kanserli Hastada Bevacizumab Tedavisi Sonrası Gecikmiş Anastomoz Kaçağı: Olgu Sunumu

Yıl 2025, Cilt: 47 Sayı: 5, 839 - 843, 04.09.2025

Arda Şakir Yılmaz , Orkhan Ulfanov , Necdet Fatih Yaşar

https://doi.org/10.20515/otd.1654126

Öz

Kolorektal kanser (KRK) tedavisinde cerrahi, kemoterapi ve hedefe yönelik ajanlar önemli rol oynar. Bevacizumab, metastatik KRK’de kullanılan bir VEGF inhibitörüdür ancak yara iyileşmesini geciktirerek anastomoz kaçağı riskini artırabilir. Bu olguda, rektum kanseri nedeniyle düşük anterior rezeksiyon yapılan 71 yaşındaki bir hastada, ameliyattan 26 ay sonra gecikmiş anastomoz kaçağı gelişmiştir. Görüntülemelerde presakral apse ve bağırsak lümeni ile bağlantılı koleksiyon saptanmış, cerrahi eksplorasyonda anastomoz ayrışması görülmüştür. Hastaya saptırıcı kolostomi açılmış ve postoperatif dönemde stabil seyretmiştir. Bu vaka, bevacizumab tedavisinin geç dönemde bile anastomoz bütünlüğünü etkileyebileceğini göstermekte ve bu hastaların uzun süreli dikkatli takibinin gerekliliğini vurgulamaktadır.

Anahtar Kelimeler

Kolorektal kanser , anastomoz kaçağı , bevacizumab

Delayed Anastomotic Leakage After Bevacizumab Therapy in rectal Cancer Patient: A Case Report

Öz

Surgery, chemotherapy, and targeted agents play crucial roles in the treatment of colorectal cancer (CRC). Bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor used in metastatic CRC, has been associated with delayed wound healing, potentially increasing the risk of anastomotic leakage. In this case, a 71-year-old patient who underwent low anterior resection for rectal cancer developed delayed anastomotic leakage 26 months after surgery. Imaging revealed a presacral abscess and a collection communicating with the intestinal lumen, and surgical exploration confirmed anastomotic dehiscence. A diverting colostomy was performed, and the patient remained stable in the postoperative period. This case highlights that bevacizumab therapy can impact anastomotic integrity even in the late postoperative period, emphasizing the need for prolonged and careful follow-up in such patients.

Anahtar Kelimeler

Colorectal cancer , anastomotic leak , bevacizumab

Kaynakça

• 1. Sneider EB, Davids JS. Effect of chemotherapy, radiation, or immunosuppression on the integrity of the intestinal anastomosis. Seminars in Colon and Rectal Surgery. WB Saunders, 2014; 105-109.
• 2. Tsalikidis C, Mitsala A, Mentonis VI, et al. Predictive Factors for Anastomotic Leakage Following Colorectal Cancer Surgery: Where Are We and Where Are We Going?, Current oncology (Toronto, Ont.), 2023;30(3):3111-3137. Published 2023 Mar 7.
• 3. Kim S, Shin JK, Park Y, et al. Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer. Frontiers in oncology, 2022;12:1018458. Published 2022 Oct 21.
• 4. Karanlik H, Kurt A, Kunduz E, et al. Effects of intraperitoneal bevacizumab administration on colonic anastomosis and early postoperative adhesion formation. Surgical innovation. 2013;20(6):559-565.
• 5. Bège T, Lelong B, Viret F, et al. Bevacizumab-related surgical site complication despite primary tumor resection in colorectal cancer patients. Annals of surgical oncology, 2009;16(4):856-860.
• 6. Nakamura H, Yokoyama Y, Uehara K, et al. The effects of bevacizumab on intestinal anastomotic healing in rabbits. Surgery today, 2016;46(12):1456-1463.
• 7. Araujo-Filho I, Menseses Rêgo AC. Neoadjuvant Immunotherapy and Intestinal Microbiota: Unraveling their roles in Anastomotic Leakage and Fistula after Colorectal Cancer Surgery: Neoadjuvant Immunotherapy and Intestinal Microbiota: Unraveling their roles in Anastomotic Leakage and Fistula after Colorectal Cancer Surgery. Journal of Surgical and Clinical Research [Internet]. 2024;15(1):117-32.
• 8. O'Hare T, McDermott R, Hannon R. Late anastomotic breakdown with bevacizumab in colorectal cancers, a case-based review. Irish journal of medical science, 2018;187(2):333-336.
• 9. Tzu-Chi H, Wen-Chun S, Ming-Jen C. Anastomotic Leakage Could be Caused by Regorafenib - A Case Report. Surgery Clinics Journal. 2018; 1(1): 1001.
• 10. Machida E, Miyakura Y, Takahashi J, et al. Bevacizumab is associated with delayed anastomotic leak after low anterior resection with preoperative radiotherapy for rectal cancer: a case report. Surgical case reports, 2019;5(1):14. Published 2019 Jan 31.
• 11. Jafari M, Tessier W, El Hajbi F, Decanter G, Mirabel X. Delayed anastomotic leakage following bevacizumab administration in colorectal cancer patients. Acta oncologica (Stockholm, Sweden), 2016;55(9-10):1250-1252.
• 12. Yoshioka Y, Uehara K, Ebata T, et al. Postoperative complications following neoadjuvant bevacizumab treatment for advanced colorectal cancer. Surgery today, 2014;44(7):1300-1306.
• 13. Baek SY, Lee SH, Lee SH. Bevacizumab induced intestinal perforation in patients with colorectal cancer. Korean Journal of Clinical Oncology, 2019, 15.1: 15-18.
• 14. Andrei LS, Popisteanu RS, Micu A et al. Double Perforation after Colorectal Cancer Surgery During Bevacizumab Treatment. Modern Medicine, 2020, 27.4: 310.
• 15. Takahashi Y, Kobayashi A, Seki H. Delayed anastomotic leakage during treatment with ramucirumab: A case report. Cancer, 2021, 5: 1-3.